MedPath

MEMORY PHARMACEUTICALS

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

A Single-Center, Double-Blind (DB) Study of MEM 3454 on P50 Sensory Gating and Mismatch Negativity in Schizophrenia Patients

Phase 2
Conditions
Schizophrenia
Interventions
Drug: Placebo for MEM 3454
First Posted Date
2008-07-31
Last Posted Date
2008-07-31
Lead Sponsor
Memory Pharmaceuticals
Target Recruit Count
12
Registration Number
NCT00725855
Locations
🇺🇸

University of Colorado Health Sciences Center, Denver, Colorado, United States

Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia

Phase 2
Conditions
Cognitive Impairment Associated With Schizophrenia
Interventions
Drug: Placebo for MEM 3454
First Posted Date
2008-01-30
Last Posted Date
2008-12-08
Lead Sponsor
Memory Pharmaceuticals
Target Recruit Count
160
Registration Number
NCT00604760
Locations
🇺🇸

CRI Worldwide, LLC at Lourdes Medical Center of Burlington County, Willingboro, New Jersey, United States

🇺🇸

Neuropsychiatric Research Center of Orange County, Santa Ana, California, United States

🇺🇸

CRC Worldwide, LLC, Philadelphia, Pennsylvania, United States

and more 40 locations

Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease

Phase 2
Completed
Conditions
Alzheimer's Disease
First Posted Date
2007-04-02
Last Posted Date
2008-05-06
Lead Sponsor
Memory Pharmaceuticals
Target Recruit Count
80
Registration Number
NCT00454870

Safety and Efficacy of MEM 1003 Versus Placebo for the Treatment of Patients With Bipolar I Disorder

Phase 2
Completed
Conditions
Bipolar Disorder With Manic or Mixed Episodes
First Posted Date
2006-09-12
Last Posted Date
2008-05-06
Lead Sponsor
Memory Pharmaceuticals
Target Recruit Count
60
Registration Number
NCT00374920

Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease

Phase 2
Completed
Conditions
Alzheimer's Disease
Interventions
Drug: Placebo for MEM 1003
First Posted Date
2005-11-23
Last Posted Date
2008-05-06
Lead Sponsor
Memory Pharmaceuticals
Target Recruit Count
183
Registration Number
NCT00257673
© Copyright 2025. All Rights Reserved by MedPath